Miles for Moffitt - Let’s Race to End Cancer
Since 2006, the annual Miles for Moffitt
event has been a great way for Moffitt team
members to join the Tampa community
and friends from all over the country for
fun and fitness – and to support lifesaving
cancer research at Moffitt Cancer Center.
Every dollar ever raised through registration
fees and donations – more than $4 million
so far - has gone directly to empower our
scientists and researchers to do the work
that is uncovering cancer’s secrets, developing
new and more effective treatments, and
bringing closer the day when cancer is no
longer a diagnosis to be feared.
The 12th annual Miles for Moffitt, held on
Saturday, May 13 at the USF Sun Dome,
was the most successful yet. Over $1 million
was raised for our fight against
cancer. Members of Moffitt’s
Neurology Department were
excited to be among the
participants (see photo).
We thank those who joined
in the race; the runners, the
walkers, the wheelchair user,
the volunteers and all the people
who donated. Without your help,
this event would not be the huge
success that it was.
Be sure to save the date for this
year’s Miles for Moffitt being held
on December 8, 2018 in Downtown
Tampa! You’ll find more information,
including sponsorship opportunities,
by visiting MilesforMoffitt.com.
Neuro-Oncology Active Clinical Trials (continued)
Moffitt Neurology Department team members and friends went the
distance in the 2017 Miles for Moffitt. Left to right: Travis Wicklund,
Melissa Wicklund, Pedro de la Fe, Ali Drury-Sibiga, Jason Stiger,
Brittany Evernden, Barbara Miller, Paul Pakidis, Caitlin Oline,
Eleni Rokakis, Adrienne Adams and Holly Wolfrum.
Trial Name MCC # Grade Prior Treatment
Y/N
Contact for
Eligibility Criteria
Brain Metastases from Solid Tumors
A Phase 2 Study of Abemaciclib in Patients with Brain Metastases
Secondary to Hormone Receptor Positive Breast Cancer,
Non-small Cell Lung Cancer, or Melanoma
18093 4 Y Sahebjam
Randomized Phase II Study: Corticosteroids + Bevacizumab vs.
Corticosteroids + Placebo (BeSt) for Radionecrosis after
Radiosurgery for Brain Metastases
19433 4 N Mokhtari
A Phase II Trial of AZD9291 (Osimertinib) with or without
Bevacizumab in Patients with EGFR Mutation Positive NSCLC
and Brain Metastases
19399 4 Y
Forsyth
A Phase 2 Trial of Pembrolizumab Plus Bevacizumab in Patients with
Metastatic Melanoma or Non-small Cell Lung Cancer with Untreated
Brain Metastases
19327 4 N
Forsyth
Surgical Intervention Trials
OsteoCool Tumor Ablation Post-Market Study (OPuS One) 19472 4 N Tran
Primary Central Nervous System Lymphoma
A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab
in Relapsed/Refractory
Primary Central Nervous System Lymphoma (PCNSL) or
Relapsed/Refractory Primary
Testicular Lymphoma (PTL)
18880 3 Y Bello
Neuro-Oncology Trials Non-Interventional
Characterization of Tumor Infi ltrating Lymphocytes from
Glioma Specimens
50173 Etame
An Early Stage Biomarker Study of A Multi-Platform Analysis of a
“Liquid Biopsy” of CSF in Patients with Leptomeningeal Disease and
Other Brain Tumors ToImprove Diagnosis and Treatment
19332 Forsyth
MOFFITT.org 2018 ISSUE | NEURON NEWS 15
/MilesforMoffitt.com
/MOFFITT.org